carbostyril has been researched along with Demyelinating Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, C; Chrzanowski, U; Kaye, J; Kipp, M; Nyamoya, S; Schmitz, C; Steinle, J | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Alon, R; Brück, W; Feigelson, S; Hayardeny, L; Pförtner, R; Raymond, E; Stadelmann, C; Timan, B; Wegner, C | 1 |
| Aharoni, R; Arnon, R; Eilam, R; Hayardeny, L; Saada, R; Sela, M | 1 |
| Brakelmann, L; Brück, W; Hagemeier, K; Hanisch, UK; Hayardeny, L; John, GR; Kramann, N; Kuhlmann, T; Pförtner, R; Pham, T; Piryatinsky, V; Regen, T; Stadelmann, C; van Rossum, D; Wegner, C; Zhang, J | 1 |
| Lassmann, H | 1 |
6 other study(ies) available for carbostyril and Demyelinating Diseases
| Article | Year |
|---|---|
Laquinimod Supports Remyelination in Non-Supportive Environments.
Topics: Animals; Brain; Cell Differentiation; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Mice; Mice, Inbred C57BL; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendrocyte Transcription Factor 2; Oligodendroglia; Quinolones; Remyelination | 2019 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Cell Movement; Demyelinating Diseases; Down-Regulation; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation Mediators; Interleukin-17; Mice; Mice, Inbred C57BL; Quinolones; T-Lymphocyte Subsets | 2010 |
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Topics: Animals; Axons; Brain-Derived Neurotrophic Factor; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Immunologic Factors; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Quinolones; T-Lymphocytes, Regulatory | 2012 |
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Topics: Animals; Astrocytes; Axons; Cuprizone; Demyelinating Diseases; Male; Mice; Myelin Sheath; NF-kappa B; Oligodendroglia; Quinolones | 2012 |
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Topics: Animals; Astrocytes; Blood-Brain Barrier; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; NF-kappa B; Oligodendroglia; Propylene Glycols; Quinolones; Sphingosine | 2012 |